| Product Name | MF | CAS | Details |
|---|
| RSS0680 | C52H64N10O6S3 | 2769753-48-0 | Details |
| P 218 | C18H25ClN4O4 | 1142407-60-0 | Details |
| HA5 | C15H10O5 | 2378406-17-6 | Details |
| P-gb-IN-1 | 2632874-49-6 | Details |
| Brentuximab | 2088770-90-3 | Details |
| Moiramide B | C25H31N3O5 | 155233-31-1 | Details |
| Glembatumumab vedotin | 1182215-65-1 | Details |
| Inotuzumab | 1660159-36-3 | Details |
| RSH-7 | C22H25FN8O | 2764609-97-2 | Details |
| Ebaresdax hydrochloride | C12H15ClN2O3S | 1334385-87-3 | Details |
| AP-C2 | C18H16N4S | 682793-07-3 | Details |
| KSK67 | C22H27N3O2 | 2566715-93-1 | Details |
| NP10679 | C23H26F3N3O3 | 2914889-88-4 | Details |
| PARP1/2/TNKS1/2-IN-1 | 2243453-32-7 | Details |
| TGFβ1-IN-3 | 2883813-58-7 | Details |
| Zilovertamab | 1643432-38-5 | Details |
| ZIM | C20H19N3O3 | 301298-87-3 | Details |
| Angiotensin 1/2 (1-9) TFA | Details |
| MitoSOX Red | C43H43IN3P | 1003197-00-9 | Details |
| SOS1-IN-15 | C28H27F3N6O2 | 2793404-47-2 | Details |
| Myosin V-IN-1 | C29H26N6O3S | 1259177-59-7 | Details |
| R 59-022 hydrochloride | C27H27ClFN3OS | 93076-98-3 | Details |
| PF-17 | C21H28N4O5S | 2697145-21-2 | Details |
| PARP-2-IN-3 | 2915650-86-9 | Details |
| OTUB1/USP8-IN-1 | C22H16ClFN2O4 | 2858800-98-1 | Details |
| GW297361 | C16H12N4O3S2 | 388627-21-2 | Details |
| HDAC-IN-57 | C21H19N3O4 | 2716217-79-5 | Details |
| pCDPK1/TgCDPK1-IN-3 | C17H18N6 | 1092788-87-8 | Details |
| 17β-HSD10-IN-1 | C16H13ClN4O3S | 2316765-78-1 | Details |
| Anti-inflammatory agent 51 | C22H22N6O6S | 2911610-03-0 | Details |
| AUTAC1 | C44H63FN8O11S | 2241669-09-8 | Details |
| DC-BPi-03 | C14H14N4O2S | 2758411-46-8 | Details |
| Sonepcizumab | 1031360-18-5 | Details |
| DATPT | C24H38N6O3.ClH | 2891582-75-3 | Details |
| USP28-IN-3 | C23H20Cl2N2O3S | 2931509-14-5 | Details |
| Senktide acetate | Details |
| GSK3-IN-3 | C24H35N3O4 | 331963-27-0 | Details |
| Theralizumab | 906068-56-2 | Details |
| Clivatuzumab | 1622075-09-5 | Details |
| Akt3 degrader 1 | C53H72N8O4 | 2836342-69-7 | Details |
| PLH1215 | 1332084-64-6 | Details |
| PCSK9-IN-10 | C18H23N5O4 | 368434-98-4 | Details |
| CYP4A11/CYP4F2-IN-1 | C15H15N3OS | 502654-40-2 | Details |
| PU.1-IN-1 | C18H22N2O2S | 873588-27-3 | Details |
| ccc_R08 | C22H19ClO6 | 2919019-72-8 | Details |
| SARS-CoV-2-IN-39 | C14H8ClF4NO3 | 2882823-03-0 | Details |
| BCAT-IN-4 | 406190-85-0 | Details |
| SID-852843 | C17H15N3O5S | 909859-19-4 | Details |
| (R)-HH2853 | C31H36F3N7O3 | 2202678-06-4 | Details |
| CYP1B1-IN-5 | C14H8INO2 | 176442-56-1 | Details |
| AXL-IN-13 | C34H41FN6O5 | 2376928-82-2 | Details |
| MyD88-IN-1 | C23H24N6O7S | 2911609-80-6 | Details |
| GSNKGAIIGLM(131602-53-4(free base)) | C45H81N13O14S | 131602-53-4 | Details |
| KM02894 | C7H9N3OS2 | 116850-74-9 | Details |
| CLK8 | C29H26N2O6 | 898920-65-5 | Details |
| (R)-BI-2852 | C31 H28 N6 O2 | 2375482-49-6 | Details |
| SFI003 | C19H17N5OS | 2361332-90-1 | Details |
| STC314 | C13H25NaO32S7 | 186295-19-2 | Details |
| Enfortumab | 1448664-46-7 | Details |
| Cbl-b-IN-5 | C17H17N5OS | 2368835-59-8 | Details |
| PLH2058 | 2525206-41-9 | Details |
| Atibeprone | C17H18N2O3S | 153420-96-3 | Details |
| TJ08 | 2924274-19-9 | Details |
| Endo-1,3-β-glucanase | 9025-37-0 | Details |
| PDCD4-IN-1 | C12H9BrClN3O | 494763-64-3 | Details |
| Bivatuzumab | 214559-60-1 | Details |
| JNJ-49095397 | C34H36N6O4 | 1220626-82-3 | Details |
| NSC243928 mesylate | C22H21N3O3S.CH4O3S | 59988-01-1 | Details |
| BPDA2 | 2907659-86-1 | Details |
| CZL55 | C20H22N2O6 | 667408-87-9 | Details |
| [Sar1, Ile8]-Angiotensin II 3TFA | C46H73N13O10 | 37827-06-8 | Details |
| TGFβ1-IN-2 | C23H30N4O4S | 2700263-58-5 | Details |
| DSPE-NHS | C49H89N2O13P | 1383932-86-2 | Details |
| Ordesekimab | 879293-15-9 | Details |
| APOBEC3G-IN-1 | C15H11NO3 | 14261-92-8 | Details |
| SMN-C2 | C24H27N5O2 | 1446311-56-3 | Details |
| Cibisatamab | 1855925-27-7 | Details |
| lorvotuzumab | 339306-30-8 | Details |
| PRMT6-IN-3 | C19H26N4O2S | 2890765-10-1 | Details |
| ENT-C225 | 2919962-53-9 | Details |
| BCPA | C22H22Cl2N2O2 | 547731-67-9 | Details |
| Xanthine oxidoreductase-IN-3 | C14H10ClN5O | 651769-78-7 | Details |
| TV 3279 | C16H20N2O2 | 209394-29-6 | Details |
| hCAII-IN-9 | C15H16ClN3O5S2 | 2878477-18-8 | Details |
| SRI-42127 | C19H20N6O | 2727872-68-4 | Details |
| Dazostinag disodium | C21H23F2N8NaO10P2S2 | 2553413-93-5 | Details |
| STING agonist-30 | 2951078-67-2 | Details |
| CpG ODN 10101 | 1234402-77-7 | Details |
| 11β-HSD1 inibitor 19 | C19H16ClF4N3O2S | 946400-19-7 | Details |
| DPTN dihydrochloride | C22H18N4OS.2ClH | 325767-87-1 | Details |
| FC-116 | 2417298-29-2 | Details |
| Xanthine oxidoreductase-IN-5 | C17H17N5O2 | 1026652-90-3 | Details |
| TNF-α-IN-9 | C17H14O4 | 2054199-25-4 | Details |
| p53 Activator 7 | C27H32F3N4OP | 2849340-59-4 | Details |
| (Rac)-SHIN2 | C23H26N4O3 | 2204289-53-0 | Details |
| Nurr1 agonist 2 | C18H14O3S | 742058-34-0 | Details |
| Nampt activator-2 | C17H15ClN4O3S | 2237268-90-3 | Details |
| GRGDSPK acetate | 144027-77-0 | Details |
| Larotinib | C24H26ClFN4O4 | 1438072-11-7 | Details |
| A2B receptor antagonist 2 hydrochloride | C12H15N5.ClH | 724-70-9 | Details |
| Product Total： Product Page： | ||||
| 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 | ||||